Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)

Benzinga

Center

High Factuality

Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)

Tuesday, Amgen Inc (NASDAQ:AMGN) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD).  Tezspire is a registered trademark of Amgen and AstraZeneca Plc (NASDAQ:AZN). Overall, tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17%, although the reduction was not statistically significant, wi…